TY - GEN
T1 - A method for quantification of calponin expression in myoepithelial cells in immunohistochemical images of ductal carcinoma in situ
AU - Gray, Elliot
AU - Mitchell, Elizabeth
AU - Jindal, Sonali
AU - Schedin, Pepper
AU - Chang, Young Hwan
N1 - Funding Information:
Acknowledgements: This research was supported by a grant from Susan G. Komen® PDF17480342 (E.M), and the Oregon Health and Science University (OHSU) Center for Spatial Systems Biomedicine.
Publisher Copyright:
© 2018 IEEE.
PY - 2018/5/23
Y1 - 2018/5/23
N2 - Ductal carcinoma in situ (DCIS) is breast cancer confined within mammary ducts, surrounded by an intact myoepithelial cell layer that prevents local invasion. A DCIS diagnosis confers increased lifetime risk of developing invasive breast cancer (IBC) and results in surgical excision with radiation, and possibly endocrine- or chemo-therapy. DCIS is known to be over treated, with associated co-morbidities. Biomarkers are needed that delineate patients at low risk of DCIS progression from patients requiring more aggressive treatment. Investigating the role of myoepithelial cell differentiation in barrier function is anticipated to provide insight into DCIS progression and delineate between low and high risk lesions. Here, we develop a high throughput technique to assess loss of myoepithelial differentiation markers. This method facilitates automated analysis of a clinically relevant histopathologic feature, as demonstrated by a high correlation with pathologist annotation (r = 0.959), and further, contributes analytical foundations to a multiplexed immunohistochemistry (IHC) approach.
AB - Ductal carcinoma in situ (DCIS) is breast cancer confined within mammary ducts, surrounded by an intact myoepithelial cell layer that prevents local invasion. A DCIS diagnosis confers increased lifetime risk of developing invasive breast cancer (IBC) and results in surgical excision with radiation, and possibly endocrine- or chemo-therapy. DCIS is known to be over treated, with associated co-morbidities. Biomarkers are needed that delineate patients at low risk of DCIS progression from patients requiring more aggressive treatment. Investigating the role of myoepithelial cell differentiation in barrier function is anticipated to provide insight into DCIS progression and delineate between low and high risk lesions. Here, we develop a high throughput technique to assess loss of myoepithelial differentiation markers. This method facilitates automated analysis of a clinically relevant histopathologic feature, as demonstrated by a high correlation with pathologist annotation (r = 0.959), and further, contributes analytical foundations to a multiplexed immunohistochemistry (IHC) approach.
KW - Calponin
KW - DCIS
KW - Feature engineering
KW - Invasive breast cancer
KW - Myoepithelial cell
UR - http://www.scopus.com/inward/record.url?scp=85048130285&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85048130285&partnerID=8YFLogxK
U2 - 10.1109/ISBI.2018.8363692
DO - 10.1109/ISBI.2018.8363692
M3 - Conference contribution
AN - SCOPUS:85048130285
T3 - Proceedings - International Symposium on Biomedical Imaging
SP - 796
EP - 799
BT - 2018 IEEE 15th International Symposium on Biomedical Imaging, ISBI 2018
PB - IEEE Computer Society
T2 - 15th IEEE International Symposium on Biomedical Imaging, ISBI 2018
Y2 - 4 April 2018 through 7 April 2018
ER -